Receiving admilparant, an oral lysophosphatidic acid receptor 1 antagonist, for 26 weeks lowered percent-predicted FVC ...

Apimeds Pharmaceuticals US (APUS) plans to raise $20 million in an initial public offering (IPO) on the week of March 10th, IPO Scoop reports. The company will issue 4,500,000 shares at $4.00-$5.00 ...

US FDA approves MED-EL USA’s SONNET 3 audio processor for MED-EL cochlear implants: Durham, North Carolina Tuesday, February 18, 2025, 15:00 Hrs [IST] MED-EL USA, a leader in im ...

First, a bit of background on the pain-drug environment ... That's why, following this recent FDA approval, Vertex stock makes a no-brainer biotech stock to buy and hold for the long term.

Apimeds Pharmaceuticals US (APUS) is planning to raise $20 million in an initial public offering on the week of March 10th, IPO Scoop reports. The company will issue 4,500,000 shares at a price of $4.

Scientists in the UK have successfully used gene therapy to restore some vision to legally blind children with an inherited retinal condition. All 11 children in the clinical trial saw improvements ...

Manufacturing: As a result of FDA approval of RYONCIL in December 2024, the US$23.0 million provision against the value of inventory manufactured and expensed in prior periods was reversed and is now ...

MED-EL USA announced today that the U.S. Food and Drug Administration approved the new SONNET 3 ... This includes reducing distracting background noises and leveraging dual microphones to allow ...

DURHAM, N.C., February 14, 2025--(BUSINESS WIRE)--MED-EL USA announced today that the U.S. Food and Drug Administration approved the new SONNET 3 audio ... This includes reducing distracting ...

The safety and efficacy of this use has not been established by the U.S. FDA. There is currently no cure for HIV or AIDS. About Lenacapavir Lenacapavir is approved in multiple countries for the ...

Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United States (U.S.) Food ...

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system ...